1647052-98-9

Upstream product

• 68280-85-3 2-acetamido-3-(4-methoxyphenyl)-2-propenoic acid 
• 28030-16-2 3-(4-methoxyphenyl)-2-oxopropanoic acid 
• 71198-72-6 4-[(4-methoxyphenyl)methylene]-2-methyl-5(4H)-oxazolone 
• 123-11-5 4-methoxy-benzaldehyde 
• 107-99-3 2-(dimethylamino)ethyl chloride 
• 112517-73-4 6-[(4-methoxyphenyl)methyl]-3,4-dihydro-3-thioxo-1,2,4-triazin-5(2H)-one 

Relevant academic research and scientific papers

Thiazole[3,2-b]-1,2,4-thiazole derivatives and application thereof

The invention belongs to the technical field of medicine and relates to thiazole[3,2-b]-1,2,4-thiazole derivatives and an application thereof. The thiazole[3,2-b]-1,2,4-thiazole derivatives comprise thiazole[3,2-b]-1,2,4-thiazole derivative compounds as well as stereoisomers and pharmaceutically applicable salts of the compounds, and a general structural formula of the compounds is represented in the specification; the thiazole[3,2-b]-1,2,4-thiazole derivatives and the pharmaceutically applicable acid-addition salts of the compounds can be combined with existing drugs or separately utilized to serve as glucose concentration dependent type insulin secretion accelerants for treatment of type II diabetes. Compared with the prior art, the compounds are the glucose concentration dependent type insulin secretion accelerants, can promote insulin secretion under high glucose concentration and do not influence insulin secretion under low glucose concentration, so that the side effect of hypoglycemia is avoided.

Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7- one derivatives as dual binding site acetylcholinesterase inhibitors

New dual binding site acetylcholinesterase (AChE) inhibitors have been designed and synthesized as a new drug candidate for the treatment of Alzheimer's disease (AD) through the binding to both catalytic and peripheral sites of the enzyme. Therefore, a se